Par Equity report 270% return on PathXL sale

Scottish venture capital firm Par Equity has sold its stake in medical technology firm PathXL to Philips for an undisclosed sum.

Par Equity said the sale of a reported seven-figure stake taken in 2012 has generated a 270 per cent tax-free return for investors.

Read more at http://www.dailyrecord.co.uk/business/business-science-technology/par-equity-report-270-return-8395358#dQWMwEYsYB5wPq91.99